| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 16, 2026 | Samsung Bioepis Grows Australia Biosimilar Portfolio to Four as PBS Default Reform Nears | By Henry Baker
Published: Jul 16 2026, 11:01 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jun 9, 2026 | SBI steps in with $1-billion funding for Sun Pharma’s Organon deal | State Bank of India (SBI) plans to join a group of global lenders in funding Sun Pharmaceutical Industries Ltd.’s $12 billion overseas acquisition, according to people familiar with the matter.
SBI, the country’s largest bank by assets, is ... |
| May 21, 2026 | Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia | announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies’ partnership in Southeast Asia.
Under the agreeme... |
| May 13, 2026 | Zydus to acquire US cancer drug company Assertio for $166.4 million in all-cash deal | Zydus Lifesciences announced on Wednesday that it had signed an agreement via its subsidiary to acquire Assertio Holdings Inc. for $166.4 million in an all-cash deal. Assertio is a Nasdaq-listed pharmaceutical company focused on specialty a... |
| May 1, 2026 | Deals Digest: PE-VC deal value recovers; Sun Pharma's Organon buy boosts M&As | Premium
Private equity (PE) and venture capital (VC) deal value recovered sharply this week, even as activity cooled. Meanwhile......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of o... |
| Apr 30, 2026 | AmChamSG Announces 2026-7 Chair and Board of Governors | Demonstrating leadership in board diversity with women governors occupying at least 50% of seats since 2021
SINGAPORE, April 30, 2026 /PRNewswire/ -- Adam Click, Regional Client Lead, Google Asia Pacific, has been elected Chair of The Ameri... |
| Apr 29, 2026 | European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe | SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for... |
| Mar 30, 2026 | Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants | SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health in... |
| Feb 25, 2026 | Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device | MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health
JERSEY CITY, N.J., February 23, 2026 — Organon (NYSE: OGN), a global healthcare company with a mission to deliver i... |
| Jan 21, 2026 | Why Sun Pharma’s hefty bid for Organon has divided investors | |
| Jan 8, 2026 | Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway | Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated fo... |
| Nov 17, 2025 | Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US | SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (B... |
| Nov 7, 2025 | Patricia Industries’ subsidiary Laborie to acquire the JADA System | Patricia Industries’ subsidiary Laborie to acquire the JADA System
Fri, Nov 07, 2025 13:32 CET Report this content
Patricia Industries’ subsidiary Laborie, a leading provider of diagnostic and therapeutic medical technology products for the... |
| Nov 5, 2025 | A New Era of Leadership: CLOC Unveils Expanded, Modernized Board to Unite the Legal Ecosystem | New board brings together seasoned legal operations executives, in-house counsel, and technology innovators to drive industry-wide transformation.
SAN JOSE, Calif., Nov. 5, 2025 /PRNewswire-PRWeb/ -- CLOC (Corporate Legal Operations Consort... |
| Oct 27, 2025 | Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more | |
| Sep 19, 2025 | European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively | SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injec... |
| Sep 2, 2025 | US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively | SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg... |
| Jun 30, 2025 | Beech Biotech awarded $1.9 million Gates Foundation grant |
Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Each year, preeclampsia causes the deaths of 70,000 mothers and 500,000 babies worldwide. Beyond that, long-ter... |
| Mar 27, 2025 | Henlius and Fosun Pharma: Navigating the Future of Healthcare Innovation | In the bustling landscape of global healthcare, two Chinese pharmaceutical giants, Henlius and Fosun Pharma, are carving their paths with innovation and strategic growth. Their recent annual results paint a vivid picture of resilience and a... |
| Mar 26, 2025 | Fosun Pharma Announces 2024 Annual Results | Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
SHANGHAI, March 26, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the G... |
| Nov 11, 2024 | The Future of Healthcare: Navigating Opportunities in Aging and Biomanufacturing | The landscape of healthcare is shifting. Two recent developments highlight this transformation: the response to China’s aging population and the rise of biomanufacturing in the United States. Both are driven by necessity and innovation. The... |
| Nov 5, 2024 | CIIE: Pharma Giants See Opportunities in China's Aging, Childless Population | (Yicai) Nov. 5 -- An overview of foreign pharmaceutical companies’ offerings at the seventh China International Import Expo reveals how drugmakers are adapting to China's aging population and new policies encouraging family planning.
A... |
| Sep 24, 2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| Sep 24, 2024 | Financial boost for five publicly traded companies |
Altamira Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics for extrahepatic targets, announced the closing of a public offering raising up to $12.0 million. The offering included Series A-1 and Series A-2 com... |
| Aug 30, 2024 | Setting data up for AI success with Coveo and Organon | Setting data up for AI success with Coveo and Organon
Generative AI (GenAI)—though ambitious in its goals—is nothing without the extensive data work that must be done before, during, and beyond implementation. Data cleanliness is a critical... |
| Apr 15, 2024 | Amid threats to IVF, National Infertility Awareness Week® Brings Awareness Activities Across the Country | National Infertility Awareness Week® take place April 21 through April 27, 2024.
RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 21 through April 27, 2024. The movement brings togethe... |
| Mar 29, 2024 | Health | Experts say Medicaid rebate change is behind inhaler price cuts | Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma and chronic obstructive pulmonary disease... |
| Mar 12, 2024 | Women’s Health Accelerator Programme’s second cycle launched by Flat6Labs, Organon | The second cycle of the Women’s Health Accelerator Programme has begun, according to announcements made by Organon, a global healthcare organization committed to enhancing women’s health, and Flat6Labs, the top seed and early-stage venture ... |
| Mar 9, 2024 | Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting | Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as well as efficacy, safety and immunogenicity profiles were comparable between... |
| Mar 8, 2024 | “Survey on Women’s Health and Careers” released on March 8th in conjunction with International Women’s D ay | Many women want to build a career through work, but more than 90% of women are concerned about health issues answer ed that it could affect th | Good and Company Co., Ltd.
“Survey on Women’s Health and Careers” released on March 8th in conjunction with International Women’s Day | Many women want to build a career through work, but more than 90% of women are concerned about health is... |
| Mar 8, 2024 | Organon Co., Ltd. Announcement of a survey on “women’s health and career” in conjunction with International Women’s Day on March 8th | Organon Co., Ltd.
Survey released on “Women’s Health and Careers” in conjunction with International Women’s Day on March 8th
……
While many women want to build a career through work,
More than 90% of women say that “health problems” can affe... |
| Mar 8, 2024 | Organon Co., Ltd. Announcement of a survey on “women’s health and career” in conjunction with International Women’s Day on March 8th | |
| Mar 8, 2024 | “Survey on Women’s Health and Careers” released on March 8th in conjunction with International Women’s D ay | Many women want to build a career through work, but more than 90% of women are concerned about health issues answer ed that it could affect th | |
| Sep 11, 2022 | Women’s Health Initiative Launches in Africa to Advance Women’s Health | What You Should Know:
– A continent-wide and dedicated women’s health initiative was launched today to advocate for and implement solutions to improve healthcare for women in Africa. The Coalition for Women’s Health In Africa (CoWHA) is the... |
| Nov 18, 2021 | Making Organon's operating model fit for the future. | Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee Experiences
Accenture to help build Organon's next generation enterprise capabilities with SAP S4/HANA® on AWS
NEW YORK - Accenture (NYSE: AC... |
| Nov 12, 2021 | Organon reports results for the third quarter ended September 30, 2021 - Form 8-K | Organon reports results for the third quarter ended September 30, 2021
• Third quarter 2021 revenue of $1,600 million
• Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing o... |
| Aug 12, 2021 | Organon : reports results for the second quarter ended June 30, 2021 and announces inaugural dividend (Form 8-K) | Organon reports results for the second quarter ended June 30, 2021 and announces inaugural dividend
· Second quarter 2021 revenue of $1,595 million
· Net income from continuing operations of $431 million, or $1.70 per diluted share; Adjuste... |
| Aug 5, 2021 | ObsEva receives USD 500 million in upfront and milestone payments | Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront... |
